It is observed that the sales of Cardiac Glycosides in South Korea are forecasted to remain steady from 2024 through 2028, each year showing a consistent value of 500.0 thousand USD. The year-on-year variation is 0% over the last two forecasted years, indicating no expected growth or decline. The Compound Annual Growth Rate (CAGR) across these five years is also 0%, denoting stable sales projections.
Future Trends to Watch
Monitoring shifts in demographic factors such as an aging population and the prevalence of heart conditions could impact demand for cardiac glycosides. Additionally, advancements in alternative treatments and possible policy changes in South Korea’s healthcare system could influence future sales trends. Keeping an eye on these variables will provide better insights for adjustments in sales strategies.
